Literature DB >> 21910036

Expression of galectin-3 in pancreatic ductal adenocarcinoma.

Matthias M Gaida1, Sylvia T Bach, Frank Günther, Billur Baseras, Darjus F Tschaharganeh, Thilo Welsch, Klaus Felix, Frank Bergmann, Gertrud M Hänsch, Moritz N Wente.   

Abstract

Galectin-3 influences neoangiogenesis, tumor cell adhesion, and tumor-immune-escape mechanisms. Hence, the expression of galectin-3 in pancreatic ductal adenocarcinoma (PDAC) was evaluated. Galectin-3 expression in PDAC cell lines was proven by the presence of intracellular protein and by release into the supernatant. Furthermore, galectin-3 was found in the majority of human tissue samples. Serum concentrations of galectin-3 in PDAC patients did not differ significantly from healthy donors and did not correlate with established tumor markers. In conclusion, galectin-3 is expressed in PDAC tissues suggesting a role in tumor development; however, no relationship between expression and clinical findings could be established.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21910036     DOI: 10.1007/s12253-011-9444-1

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  31 in total

Review 1.  Pancreatic carcinoma.

Authors:  A L Warshaw; C Fernández-del Castillo
Journal:  N Engl J Med       Date:  1992-02-13       Impact factor: 91.245

2.  Clinical significance of Galectin-3 in clear cell renal cell carcinoma.

Authors:  Manabu Sakaki; Tomoharu Fukumori; Tomoya Fukawa; Essam Elsamman; Avirmed Shiirevnyamba; Hiroyoshi Nakatsuji; Hiro-omi Kanayama
Journal:  J Med Invest       Date:  2010-02

3.  Cancer statistics, 2010.

Authors:  Ahmedin Jemal; Rebecca Siegel; Jiaquan Xu; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2010-07-07       Impact factor: 508.702

4.  Galectin-3 and proliferating cell nuclear antigen (PCNA) expression in papillary thyroid carcinoma.

Authors:  D Cvejic; S Savin; I Petrovic; S Selemetjev; I Paunovic; S Tatic; M Havelka
Journal:  Exp Oncol       Date:  2005-09

5.  Clinical significance of the expression of galectin-3 and Pim-1 in laryngeal squamous cell carcinoma.

Authors:  Ji Yun Choi; Sung Il Cho; Nam Yong Do; Cha Young Kang; Sung Chul Lim
Journal:  J Otolaryngol Head Neck Surg       Date:  2010-02

Review 6.  The role of galectin-3 in promotion of the inflammatory response.

Authors:  Fu-Tong Liu; Daniel K Hsu
Journal:  Drug News Perspect       Date:  2007-09

7.  Clinicopathological significance of galectin-3 expression in ductal adenocarcinoma of the pancreas.

Authors:  Takeshi Shimamura; Michiie Sakamoto; Yoshinori Ino; Kazuaki Shimada; Tomoo Kosuge; Yasuto Sato; Katsuaki Tanaka; Hisahiko Sekihara; Setsuo Hirohashi
Journal:  Clin Cancer Res       Date:  2002-08       Impact factor: 12.531

8.  Serum level of galectin-3 in human bladder cancer.

Authors:  Manabu Sakaki; Natsuo Oka; Ryoichi Nakanishi; Kunihisa Yamaguchi; Tomoharu Fukumori; Hiro-Omi Kanayama
Journal:  J Med Invest       Date:  2008-02

9.  Differential expression of galectin-1 and galectin-3 in thyroid tumors. Potential diagnostic implications.

Authors:  X C Xu; A K el-Naggar; R Lotan
Journal:  Am J Pathol       Date:  1995-09       Impact factor: 4.307

10.  Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction.

Authors:  Rudolf A de Boer; Dirk J A Lok; Tiny Jaarsma; Peter van der Meer; Adriaan A Voors; Hans L Hillege; Dirk J van Veldhuisen
Journal:  Ann Med       Date:  2010-12-28       Impact factor: 4.709

View more
  8 in total

Review 1.  Mucins in pancreatic cancer and its microenvironment.

Authors:  Sukhwinder Kaur; Sushil Kumar; Navneet Momi; Aaron R Sasson; Surinder K Batra
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-07-16       Impact factor: 46.802

2.  Human umbilical cord mesenchymal stem cell-derived exosomes carrying hsa-miRNA-128-3p suppress pancreatic ductal cell carcinoma by inhibiting Galectin-3.

Authors:  X Xie; J Ji; X Chen; W Xu; H Chen; S Zhu; J Wu; Y Wu; Y Sun; W Sai; Z Liu; M Xiao; B Bao
Journal:  Clin Transl Oncol       Date:  2021-11-23       Impact factor: 3.405

3.  Synthesis and functionalization of protease-activated nanoparticles with tissue plasminogen activator peptides as targeting moiety and diagnostic tool for pancreatic cancer.

Authors:  Sophie Dobiasch; Szilard Szanyi; Aleko Kjaev; Jens Werner; Albert Strauss; Christian Weis; Lars Grenacher; Katya Kapilov-Buchman; Liron-Limor Israel; Jean-Paul Lellouche; Erica Locatelli; Mauro Comes Franchini; Jennifer Vandooren; Ghislain Opdenakker; Klaus Felix
Journal:  J Nanobiotechnology       Date:  2016-12-19       Impact factor: 10.435

4.  Hypoxia‑induced galectin‑3 enhances RhoA function to activate the motility of tumor cells in non‑small cell lung cancer.

Authors:  Yoko Kataoka; Yasuhiko Ohshio; Koji Teramoto; Tomoyuki Igarashi; Tohru Asai; Jun Hanaoka
Journal:  Oncol Rep       Date:  2018-12-07       Impact factor: 3.906

5.  Epithelial-to-mesenchymal transition in pancreatic ductal adenocarcinoma and pancreatic tumor cell lines: the role of neutrophils and neutrophil-derived elastase.

Authors:  Thomas Grosse-Steffen; Thomas Giese; Nathalia Giese; Thomas Longerich; Peter Schirmacher; G Maria Hänsch; Matthias M Gaida
Journal:  Clin Dev Immunol       Date:  2012-11-20

6.  Role of galectins in lung cancer.

Authors:  Wei-An Chang; Ming-Ju Tsai; Po-Lin Kuo; Jen-Yu Hung
Journal:  Oncol Lett       Date:  2017-09-04       Impact factor: 2.967

7.  Galectin-3 Released by Pancreatic Ductal Adenocarcinoma Suppresses γδ T Cell Proliferation but Not Their Cytotoxicity.

Authors:  Daniel Gonnermann; Hans-Heinrich Oberg; Marcus Lettau; Matthias Peipp; Dirk Bauerschlag; Susanne Sebens; Dieter Kabelitz; Daniela Wesch
Journal:  Front Immunol       Date:  2020-06-30       Impact factor: 7.561

Review 8.  Prognostic and diagnostic significance of galectins in pancreatic cancer: a systematic review and meta-analysis.

Authors:  Qiqing Sun; Yiyin Zhang; Mengqi Liu; Zeng Ye; Xianjun Yu; Xiaowu Xu; Yi Qin
Journal:  Cancer Cell Int       Date:  2019-11-21       Impact factor: 5.722

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.